The ankle brachial index exhibits better association with cardiovascular outcomes than interarm systolic blood pressure difference in patients with type 2 diabetes

Liang-Yu Lin, PhD\textsuperscript{a,b}, Chi-Min Hwu, MD\textsuperscript{a,b}, Chia-Huei Chu, MD\textsuperscript{b,c}, Justin G.S. Won, MD\textsuperscript{a,b}, Harn-Shen Chen, PhD\textsuperscript{a,b}, Li-Hsin Chang, MD\textsuperscript{b,d}\textsuperscript{*}

Abstract

Increased interarm systolic blood pressure difference (IASBPD) is associated with cardiovascular prognosis in the general population. This study aimed to evaluate whether IASBPD or ankle brachial index (ABI) is strongly associated with cardiovascular outcomes in patients with type 2 diabetes.

Total 446 type 2 diabetes followed up for a mean 5.8 years divided by ABI (<0.9 vs ≥0.9) or IASBPD (<10 vs ≥10 mm Hg). The primary outcome was a composite of all-cause mortality, hospitalization for coronary artery disease, nonfatal stroke, cardiac, or peripheral revascularization, amputations, and diabetic foot syndrome. The secondary endpoint was all-cause mortality.

Sixty-four composite events and 17 deaths were identified. The primary and secondary outcomes were higher than those in the group with ABI <0.9 vs ABI ≥0.9 (32.8% vs 11.6%, P < .005 for primary outcome; 14.0% vs 2.3%, P < .005 for all-cause mortality) but IASBPD cannot exhibit a prognostic value. ABI <0.9 was also the dominant risk factor of both endpoints demonstrated by multivariate Cox proportional analysis (composite events: adjusted hazard ratio [HR], 2.39; 95% confidence interval [CI], 1.26–4.53; P = .007; all-cause mortality: adjusted HR, 3.27: 95% CI, 1.91–5.60; P < .001).

The ABI was more associated with cardiovascular outcomes in patients with diabetes than IASBPD.

Abbreviations: ABI = ankle brachial index, CAD = coronary artery disease, IASBPD = interarm systolic blood pressure difference, PAD = peripheral arterial disease, T2DM = type 2 diabetes mellitus.

Keywords: ankle brachial index, cardiovascular outcomes, interarm systolic blood pressure difference, type 2 diabetes mellitus

1. Introduction

Diabetes mellitus affected 415 million individuals in 2015 worldwide, and the number is expected to increase to 642 million by 2040 with the increase of economic burden.\textsuperscript{[1]} Type 2 diabetes mellitus (T2DM) is associated with chronic complications related to the impairment of macro- and microvascular beds, which can be well explained by detrimental influences on vascular biology. The relative risk of all-cause mortality in subjects with diabetes were estimated by Emerging Risk Factors Collaboration which including 689,300 participants and showed the all-cause mortality of T2DM were double and equivalent to those with history of ischemic stroke or myocardial infarction.\textsuperscript{[2]} Furthermore, approximately three-fourth of patients with type 2 diabetes die of cardiovascular disease-related events and appears to have little or no excess risk of major adverse cardiovascular events (MACE) compared with the general population.\textsuperscript{[3,4]} In addition, the 18-year-follow-up population-based study in Finland showed that patients with type 2 diabetes had a 1.9-fold increased risk of mortality caused by coronary artery disease (CAD) compared with those without diabetes and without a prior history of CAD.\textsuperscript{[5]}

According to the reports of National Health and Nutrition Examination Survey, Patients with type 2 diabetes have a 2.7-fold increased risk of peripheral arterial disease (PAD) compared with the general population.\textsuperscript{[6]} The difference in systolic blood
pressures between arms is associated with PAD, cerebrovascular disease, and increased cardiovascular and all-cause mortality.\[^1\] Interarm systolic blood pressure difference (IASBPD) of ≥10 mm Hg has been correlated with cardiovascular events in the general population and in patients with chronic kidney disease or vascular disease.\[^7\]–\[^9\] The prevalence of IASBPD more than 10 mm Hg between arms in patients with diabetes is 9% to 10% in the previous reports.\[^10\]–\[^12\]\ Risk of target organ damage of the kidney, retina, and heart was increasing concordant with higher IASBPD and the IASBPD was also associated with cardiovascular mortality.\[^12\]–\[^13\]\ Ankle brachial index (ABI), measured as a ratio of ankle-to-arm systolic blood pressure, is also a validated noninvasive procedure that is used to diagnose PAD. Lee et al showed that an ABI < 0.9 increased the credibility of the model for predicting the risk of fatal myocardial infarction after adjusting for conventional risk factors in the Edinburgh Artery Study.\[^14\]\ However, the association between ABI and cardiovascular outcomes in general populations was not consistent to the patients with diabetes. A population-based study showed that the association of ABI with all-cause mortality and with cardiovascular mortality was similar regardless of a history of diabetes after a prospective follow-up for 19 years.\[^15\]\ Furthermore, Mostaza et al demonstrated that ABI was associated with MACE and all-cause mortality patients without diabetes but the association was not found in those with diabetes.\[^16\]\ The controversial association between ABI and prognosis in patients with diabetes highlights the need for alternative methods of assessing vascular disease and predicting outcomes of diabetes.

The present study aimed to assess the association of ABI and IASBPD with cardiovascular outcomes, and to determine whether ABI or IASBPD is better associated with cardiovascular outcomes in patients with diabetes.

2. Materials and methods

2.1. Patient population and clinical data

This retrospective chart review study was conducted in accordance with the principles of Declaration of Helsinki and Title 45, US Code of Federation Regulations, Part 46, Protection of Human Subjects, revised November 13, 2001, effective December 13, 2001. Ethical approval was obtained from the Ethics Committee of Taipei Veterans General Hospital, Taiwan. The demographic and anthropometric characteristics, history of CAD or cerebrovascular disease, ABI, and medications in patients with T2DM who were registered in the diabetes share-care program of the division of endocrinology and metabolism of Taipei Veterans General Hospital from July 15, 2003 to December 31, 2007 were reviewed. All measurements of the ABI and IASBPD simultaneously were recorded by an Omron noninvasive vascular screening device (VP-1000; Omron Matsusaka Company, Kubocho, Japan) for screening of PAD. Body mass index was calculated as the weight (kg) divided by the square of height (meters). The IASBPD was defined as the difference of systolic blood pressure between the arms. The laboratory results within 3 months before or after ABI measurement, including hemoglobin A1C level, serum creatinine level, estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease formula, lipid profiles, and 2 consecutive daily urinary albumin excretions, were recorded.

2.2. Groups and research endpoint definition

The enrolled patients were divided into 2 groups based on ABI (≥ 10 mm Hg or < 0.9) or IASBPD (≥ 10 mm Hg or < 10 mm Hg). The clinical outcomes from ABI measurement up to August 2012 were retrospectively reviewed. The primary endpoint was a composite of all-cause mortality, hospitalization for CAD, stroke, carotid or peripheral revascularization, lower limb amputation, and hospitalization for diabetic foot syndrome. The secondary outcome was the all-cause mortality in the different groups.

2.3. Statistics

Continuous variables were demonstrated as mean ± standard deviation and the independent analysis was used to comparing the variance. Categorical variables were presented as numbers and portions which were compared by the method of Pearson Chi-squared test. The correlation between ABI and IASBPD was tested by the method of liner correlation and the correlation between ABI < 0.9 and IASBPD ≥ 10 mm Hg was examination by kappa coefficient. The primary and secondary endpoints were analyzed by Kaplan–Meier analysis and the cumulative event-free probabilities of each group were compared by the log-rank test. The univariate Cox proportional analysis was used to identify all relevant variables and the P < .1 is the criteria for further subjecting to multivariate Cox proportional analysis which the hazard ratio (HR) as well as corresponding probability values was calculated. The SPSS software package (version 18; IBM Corporation, Armonk, NY) was used for the above analysis.

3. Results

3.1. Baseline characteristics

We analyzed the medical records of 446 patients with T2DM who were followed up of 3.6 to 6.1 years and the mean duration was 5.8 years (standard deviation 0.5 year). All baseline characteristics of the patients in the 2 groups divided by either ABI or IASBPD are listed in Table 1. The groups with ABI ≥ 0.9 and ABI < 0.9 consisted of 388 and 58 patients, respectively. The groups with IASBPD ≥ 10 mm Hg and IASBPD < 10 mm Hg consisted of 359 and 87 patients, respectively. After grouping based on ABI, the proportion of men and smoking, daily urine albumin excretion, HbA1c level, eGFR, and use of antplatelets were higher and diabetes duration was longer in patients with ABI < 0.9. After grouping based on IASBPD, body mass index and systolic blood pressure were higher, but ABI was lower in the group with IASBPD ≥ 10 mm Hg. The result of linear correlation between ABI and IASBPD was significant (correlation coefficient = −0.245, P < 0.001). Furthermore, the correlation between ABI < 0.9 and IASBPD ≥ 10 mm Hg was also significant (Kappa coefficient 0.093, P = 0.043).

3.2. Primary and secondary outcomes

A total of 64 composite events among study subjects were recorded during the follow-up period. The patients with an ABI of < 0.9 had higher composite event rates than those with an ABI ≥ 0.9 (log-rank test: 32.8% vs 11.6%, P < .005) (Fig. 1A). No significant difference in composite events was observed between patients with IASBPD < 10 mm Hg and those with IASBPD ≥ 10 mm Hg in this analysis (log-rank test: 16.1% vs 13.9%, P = 0.560) (Fig. 1B). Similarly, the all-cause mortality rate in patients
Table 1
Baseline characteristics of subjects with type 2 diabetes grouped by ABI and IASBPD.

|                     | ABI       | IASBPD, mm Hg | P value | ABI       | IASBPD, mm Hg | P value |
|---------------------|-----------|---------------|---------|-----------|---------------|---------|
|                     | All (446) | ≥0.9 (n = 388)| <0.9 (n = 58) | P value | All (446) | ≥10 (n = 359)| <10 (n = 87) |
| Age                 | 67.6 ± 8.6| 67.5 ± 8.6    | 68.4 ± 8.7  | .45      | 67.6 ± 8.6  | 67.7 ± 8.6    | 67.3 ± 8.5    | .74 |
| Male gender, n (%)  | 241 (54)  | 202 (52)      | 39 (67)    | .03      | 241 (54)    | 190 (53)      | 51 (58)       | .33 |
| Smoking, n (%)      | 44 (10)   | 31 (8)        | 13 (22)    | .006     | 44 (10)     | 35 (9)        | 9 (10)        | .60 |
| Coronary artery disease, n (%) | 92 (21) | 78 (20)      | 14 (24)    | .47      | 92 (21)     | 76 (21)       | 16 (18)       | .56 |
| Cerebral vascular disease, n (%) | 29 (7)  | 23 (6)        | 6 (10)     | .19      | 29 (7)      | 26 (7)        | 3 (3)         | .19 |
| Diabetes duration, yr | 11.1 ± 7.9 | 10.6 ± 7.9    | 14.6 ± 7.3 | .001     | 11.1 ± 7.9  | 10.8 ± 7.9    | 12.2 ± 8.0    | .19 |
| Body mass index     | 25.4 ± 4.1| 25.5 ± 3.9    | 25.1 ± 5.4 | .54      | 25.4 ± 4.1  | 25.1 ± 4.0    | 26.8 ± 4.0    | .001 |
| Systolic blood pressure, mm Hg | 133 ± 15 | 133 ± 15     | 135 ± 16   | .45      | 133 ± 15    | 133 ± 15      | 137 ± 15      | .02 |
| Diastolic blood pressure, mm Hg | 76 ± 9  | 76 ± 9        | 75 ± 9     | .75      | 76 ± 9      | 75 ± 10       | 79 ± 9        | .08 |
| Pulse pressure, mm Hg | 57 ± 12 | 57 ± 12      | 59 ± 14    | .21      | 57 ± 12     | 56 ± 12       | 59 ± 13       | .10 |
| ABI                 | 1.03 ± 0.14| 1.07 ± 0.08  | 0.74 ± 0.11 | <.001    | 1.03 ± 0.14 | 1.05 ± 0.14   | 0.97 ± 0.13   | <.001 |
| Daily urine albumin, mg/d | 42.2 ± 100.4 | 43.2 ± 97.7 | 74.9 ± 114.4 | .03     | 42.2 ± 100.4 | 48.4 ± 103.4  | 42.5 ± 87.8  | .63 |
| HbA1C, %            | 8.0 ± 1.8  | 7.9 ± 1.7     | 8.8 ± 1.8  | .001     | 8.0 ± 1.8   | 8.0 ± 1.7     | 8.1 ± 1.9     | .75 |
| HbA1C, mmol/mol     | 64.6 ± 19.9| 63.4 ± 19.6  | 73.2 ± 19.8 | .001     | 64.5 ± 19.6 | 65.3 ± 20.9   | 65 ± 7.5      | .75 |
| Total cholesterol, mg/dL | 186 ± 37 | 185 ± 36     | 195 ± 42   | .07      | 186 ± 37    | 187 ± 37      | 182 ± 34      | .26 |
| LDL-c, mg/dL        | 114 ± 31  | 114 ± 31      | 121 ± 30   | .13      | 114 ± 31    | 115 ± 31      | 112 ± 31      | .37 |
| HDL-C, mg/dL        | 50 ± 12   | 50 ± 12       | 48 ± 11    | .13      | 50 ± 12     | 50 ± 12       | 49 ± 11       | .43 |
| Triglyceride, mg/dL | 177 ± 151 | 176 ± 155     | 185 ± 114  | .70      | 177 ± 151   | 177 ± 153     | 178 ± 140     | .98 |
| eGFR, mL/min        | 71 ± 23   | 72 ± 23       | 63 ± 22    | .01      | 71 ± 23     | 72 ± 22       | 70 ± 26       | .57 |
| ACEI/ARB, n (%)      | 186 (42)  | 160 (41)      | 26 (45)    | .54      | 186 (42)    | 149 (41)      | 37 (42)       | .89 |
| Antiplatelet, n (%)  | 120 (27)  | 97 (25)       | 23 (39)    | .12      | 120 (27)    | 91 (25)       | 29 (33)       | .13 |
| Statin, n (%)        | 114 (26)  | 97 (25)       | 17 (29)    | .44      | 114 (26)    | 89 (24)       | 25 (28)       | .47 |
| β-blocker            | 89 (20)   | 80 (20)       | 9 (15)     | .39      | 89 (20)     | 74 (20)       | 15 (17)       | .46 |

ABI = ankle brachial index, ACEI = angiotensin converting enzyme inhibitor, ARB = angiotensin II receptor blockade, eGFR = estimated glomerular filtration rate, HbA1C = hemoglobin A1C, HDL-C = high-density lipoprotein cholesterol, IASBPD = interarm systolic blood pressure difference, LDL-C = low-density lipoprotein cholesterol. Data are expressed as numbers and percentage in noncontinuous variables and mean ± standard difference in continuous variables.

Figure 1. Kaplan–Meier curve showing the cumulative event-free probability of composite events in patients with diabetes grouped by ankle brachial index (ABI) (≥0.9 vs <0.9) (A) and interarm systolic blood pressure difference (IASBPD) (≥10 vs <10 mm Hg) (B). ∗P < .001 compared to patients with ABI ≥0.9.
with ABI < 0.9 was worse than that in patients with ABI ≥ 0.9 (log-rank test: 14.0% vs 2.3%, P < .005) but this was not observed when the patients were grouped by IASBPD ≥ 10 or < 10 mm Hg (log-rank test: 4.6% vs 3.6%, P = .555) (Fig. 2A, B).

### 3.3. Univariate and multivariate regression analyses of ABI and IASBPD

Table 2 lists the results of the univariate Cox proportional analyses between variables and composite events or all-cause mortality. The presence of ABI < 0.9, older age, pulse pressure, diabetes duration, smoking history, history of CAD, eGFR and cholesterol level were significantly associated with composite events. ABI < 0.9, older age, pulse pressure, diabetes duration, history of CAD, and eGFR were significantly associated with all-cause mortality. After adjusting for age, pulse pressure, diabetes duration, smoking history, eGFR, and low-density lipoprotein cholesterol level, ABI < 0.9 was the dominant factor associated with composite events (HR, 2.39; 95% confidence interval [CI], 1.26–4.53, P = .007) and all-cause mortality (HR, 6.27; 95% CI, 2.06–19.04, P = .001) (Table 2). In contrast, IASBPD ≥ 10 mm Hg showed no association with composite events or all-cause mortality in univariate or multivariate analysis (Table 2).

### 3.4. Regression analyses of ABI and IASBPD divided into quartiles

We divided all patients into quartiles based on ABI and IASBPD to analyze the risk of clinical outcomes. Table 3 shows the Cox proportional hazard analyses for the associations of ABI and IASBPD in quartiles with composite events and all-cause mortality. Only patients in the lowest quartile of ABI had a significant risk of composite events (HR, 3.27; 95% CI, 1.64–6.49, P < .01) and all-cause mortality (HR, 13.26; 95% CI, 1.72–102.71, P = .01). However, this association was not found when patients were divided based on IASBPD.

### 4. Discussion

In the present study, ABI < 0.9 rather than IASBPD > 10 mm Hg exhibited a significant association with composite events and all-cause mortality in patients with T2DM. The tremendous increment of risk in cardiovascular outcomes was found in the lowest quartile group of ABI. The risk of cardiovascular events increased along with increment in IASBPD; however, the HR of the highest quartile group with IASBPD majorly > 10 mm Hg did not reach statistical significance. Neither ABI < 0.9 plus IASBPD ≥ 10 mm Hg (data not shown) nor IASBPD associated with all-cause mortality demonstrated that the non-HDL-cholesterol was less important factor to be influenced on the risk of composite events and all-cause mortality in this analysis comparing ABI.

The ABI was found to be the dominant determining factor associated with cardiovascular outcomes in patients with T2DM in the present study and this finding was consistent with previous studies in patients with diabetes. Patients with PAD might receive less-intensive medical therapy according to the Global Registry of Acute Coronary Events study, and a history of PAD was associated with worse cardiovascular outcomes. However, Hanssen et al reported a paradoxical association, which showed no significant difference in the association of ABI with all-cause mortality and cardiovascular mortality between patients with and without diabetes mellitus. The stiffness and calcification of the arteries in patients with diabetes may explain the paradoxical association, and the cut-off ABI value for the diagnosis of peripheral vascular disease might be modified. The theory was evidenced by an epidemiologic study conducted...
by Yan et al. Even borderline ABI, defined as ABI between 0.90 and 0.99, was associated with retinopathy, macroalbuminuria, chronic kidney disease, and stroke in patients with T2DM. Moreover, ABI also predicts rapid renal function decline, except for major cardiovascular events, in patients with atrial fibrillation. Taken together, though the optimal threshold of ABI for the diagnosis of peripheral vascular disease and prediction of outcomes of diabetes has not been completely clarified, ABI per se is still a predictor of cardiovascular outcomes in patients with T2DM.

Furthermore, ABI plays a complementary role in risk stratification of cardiovascular disease. The Framingham risk score is a well-known validated tool to assess cardiovascular risk factors and identify high-risk individuals among individuals without diabetes. Additional parameters are needed together with the Framingham risk score to assess cardiovascular risk, particularly for asymptomatic individuals with diabetes. ABI was considered as a parameter to improve the accuracy of cardiovascular risk prediction beyond the Framingham risk score. A device can obtain IASBPD and ABI simultaneously, preventing the bias of measurement resulting from discrepancy of different devices or timing of data collection; therefore, direct comparison between ABI and IASBPD was reasonable in the present study. Increased differences in blood pressure between limbs are recognized as the consequence of PAD. IASBPD was indicated to be associated with pulse-wave velocity and carotid intima medial thickness. However, the IASBPD was not associated with primary or secondary outcomes in our cohort of patients with T2DM. The IASBPD was associated with some parameters, which were associated with cardiovascular outcomes, but the association of IASBPD with cardiovascular outcomes cannot be found because the actual mechanisms of differences of blood pressure between limbs are not completely understood in patients with diabetes. Furthermore, the normal range threshold seems to be changed in different populations, except for elusive mechanisms of IASBPD. Several reports described IASBPD > 10 mm Hg to be associated with elevated cardiovascular event rates, but 15 mm Hg seems to be a more appropriate threshold for diabetes. We did not find an association between IASBPD and cardiovascular outcomes in the present study, and even the highest quartile group of IASBPD included patients with IASBPD > 9 mm Hg. In addition, IASBPD was also not associated with all-cause mortality in the previous cohort study. Another possible explanation for neutral effects on outcomes of IASBPD was the influence of medications. Our patients were being treated with several medications including angiotensin converting enzyme inhibitor, angiotensin II receptor blockade, statin, beta-blocker, or antiplatelet drugs. The use of these medications might influence the association between IASBPD and all-cause mortality, but there was no imbalance in the use of specific medications in our study. Further studies to assess the impact of medication on cardiovascular outcomes in diabetes with or without PAD should be conducted in the future.

### Table 2

**Result of univariate and multivariate Cox proportional hazard model for association of parameters with composite events and all-cause mortality.**

| Composite events | HR     | 95% CI  | P value |
|------------------|--------|---------|---------|
| **Univariate**   |        |         |         |
| ABI < 0.9        | 3.27   | 1.91–6.06 | < .001 |
| IASBPD ≥ 10 mm Hg| 1.19   | 0.65–2.16 | .56     |
| Age              | 1.03   | 1.00–1.08 | .02     |
| Pulse pressure   | 1.02   | 1.00–1.03 | .04     |
| Diabetic duration| 1.04   | 1.01–1.07 | .003    |
| Smoking          | 2.65   | 1.38–5.56 | .001    |
| CAD history      | 2.68   | 1.61–4.47 | < .001 |
| eGFR             | 0.98   | 0.97–0.99 | .001    |
| Cholesterol      | 1.00   | 1.00–1.01 | .02     |
| **Multivariate** |        |         |         |
| ABI < 0.9        | 2.39   | 1.26–4.53 | .007    |
| eGFR             | 0.98   | 0.97–1.00 | .043    |
| Cholesterol      | 1.00   | 1.00–1.01 | .03     |
| Diabetic duration| 1.05   | 1.01–1.08 | .004    |
| CAD history      | 2.70   | 1.47–5.00 | .001    |

### Table 3

**Result of cox proportional hazard model for the associations of quartile of ABI and IASBPD with composite events and all-cause mortality.**

| Composite events | HR     | 95% CI  | P value |
|------------------|--------|---------|---------|
| **ABI**          |        |         |         |
| 1st quartile     | 1      | –        | –       |
| 2nd quartile     | 0.93   | 0.39–2.19 | .86     |
| 3rd quartile     | 1.02   | 0.44–2.37 | .94     |
| 4th quartile     | 3.27   | 1.64–6.49 | .001    |
| **IASBPD**       |        |         |         |
| 1st quartile     | 1      | –        | –       |
| 2nd quartile     | 0.54   | 0.22–1.30 | .17     |
| 3rd quartile     | 1.24   | 0.61–2.53 | .53     |
| 4th quartile     | 1.83   | 0.94–3.53 | .07     |

All-cause mortality

| Composite events | HR     | 95% CI  | P value |
|------------------|--------|---------|---------|
| **Univariate**   |        |         |         |
| ABI < 0.9        | 6.31   | 2.43–16.36 | < .001 |
| IASBPD ≥ 10 mm Hg| 0.71   | 0.22–2.21 | .35     |
| Age              | 1.17   | 1.10–1.25 | < .001 |
| Pulse pressure   | 1.04   | 1.01–1.08 | .009    |
| Diabetic duration| 1.09   | 1.04–1.15 | < .001 |
| CAD history      | 2.94   | 1.08–8.33 | .03     |
| eGFR             | 0.96   | 0.94–0.98 | < .001 |
| **Multivariate** |        |         |         |
| ABI < 0.9        | 6.27   | 2.06–19.04 | .001 |
| eGFR             | 1.21   | 1.11–1.32 | < .001 |
| Pulse pressure   | 1.05   | 1.01–1.08 | .009    |
| eGFR             | 0.96   | 0.94–0.99 | .02     |
| Diabetic duration| 1.10   | 1.03–1.17 | .002    |

**ABI** = ankle brachial index, **IASBPD** = interarm systolic blood pressure difference.

LDL-C = low-density lipoprotein cholesterol.

* Adjust with IASBPD, age, pulse pressure, diabetes duration, smoking, CAD history, eGFR, cholesterol.

† Adjust with age, pulse pressure, diabetes duration, smoking, LDL-C, eGFR.
This study has some limitations. First, this is a retrospective study conducted in a single center in Taiwan; therefore, the selection bias is inevitable, and whether the results can be applied to other ethnicities should be verified by further research. Second, the numbers of patients with diabetes with ABI < 0.9 were relatively too small compared with the general population; however, the prevalence rate is consistent with the present study.[13] Furthermore, multicenter prospective studies are warranted to confirm the conclusion of our study. Finally, the medical histories and cardiovascular events based on medical records might have led to bias in this analysis.

In conclusion, ABI shows a better association with cardiovascular outcomes, including composite cardiovascular events and all-cause mortality, than noninvasive modality would be recommended in asymptomatic patients with T2DM.

Acknowledgment

The authors thank the Medical Sciences and Technology Building of Taipei Veterans General Hospital for providing them with an experimental space and facilities.

Author contributions

Analysis data: LYL, CHC, LHC.

Cases contributor: CMH, JGWS, LYL.

Study design and data collection: LYL, CMH, LHC.

Writing the manuscript: LYL, CHC, LHC.

Data curation: Justin G.S. Won.

Methodology: Chia-Huei Chu.

Supervision: Chii-Min Hwu, Harn-Shen Chen.

Writing – original draft: Liang-Yu Lin.

Writing – review & editing: Li-Hsin Chang.

Li-Hsin Chang orcid: 0000-0002-6969-5432.

References

[1] Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017;128:40–50.

[2] Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39.

[3] Hammoud T, Tanguay JF, Bourassa MG. Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol 2000;36:335–65.

[4] Rawshani A, Rawshani A, Franzen S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2018;379:633–44.

[5] Juutilainen A, Lehto S, Ronnemaa T, et al. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005;28:2901–7.

[6] Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110: 738–43.

[7] Clark CE, Taylor RS, Shore AC, et al. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet 2012;379: 905–14.

[8] Weinberg J, Gona P, O’Donnell CJ, et al. The systolic blood pressure difference between arms and cardiovascular disease in the Framingham Heart Study. Am J Med 2014;127:209–15.

[9] Quiroga B, Galan I, Garcia de Vinuesa S, et al. Interarm systolic blood pressure as a predictor of cardiovascular events in patients with chronic kidney disease. Nephrol Dial Transplant 2015;30:801–6.

[10] Kleefstra N, Houvereling ST, Meyboom-de Jong B, et al. Measuring the blood pressure in both arms is of little use; longitudinal study into blood pressure differences between both arms and its reproducibility in patients with diabetes mellitus type 2 [in Dutch]. Ned Tijdschr Geneeskd 2007; 151:1509–14.

[11] Clark CE, Greaves CJ, Evans PH, et al. Inter-arm blood pressure difference in type 2 diabetes: a barrier to effective management? Br J Gen Pract 2009;59:428–32.

[12] Spannella F, Giuliani F, Fedecostante M, et al. Interarm blood pressure differences predict target organ damage in type 2 diabetes. J Clin Hypertens (Greenwich) 2017;19:472–8.

[13] Clark CE, Steele AM, Taylor RS, et al. Inter-arm blood pressure difference in people with diabetes: measurement and vascular and mortality implications: a cohort study. Diabetes Care 2014;37:1613–20.

[14] Lee AJ, Price JF, Russell MJ, et al. Improved prediction of fatal myocardial infarction using the ankle brachial index in addition to conventional risk factors: the Edinburgh Artery Study. Circulation 2004;110:3075–80.

[15] Hanssen NM, Huijbers MS, Schalkwijk CG, et al. Associations between the ankle-brachial index and cardiovascular and all-cause mortality are similar in individuals without and with type 2 diabetes: nineteen-year follow-up of a population-based cohort study. Diabetes Care 2012;35:1731–5.

[16] Mostaza JM, Manzano L, Suarez C, et al. Different prognostic value of silent peripheral artery disease in type 2 diabetic and non-diabetic subjects with stable cardiovascular disease. Atherosclerosis 2011; 214:191–5.

[17] Chung LH, Hwu CM, Chu CH, et al. The ankle brachial index exhibits better association of cardiovascular prognosis than non-high-density lipoprotein cholesterol in type 2 diabetes. Am J Med Sci 2016;351:492–8.

[18] Tauci I, Verim S, Kabul HK, et al. Ankle brachial index as a predictor of subclinical atherosclerosis in the elderly. Int J Cardiol 2012;160:147.

[19] Papamichael CM, Lekakis JP, Stamatelopoulos KS, et al. Ankle-brachial index as a predictor of the extent of coronary atherosclerosis and cardiovascular events in patients with coronary artery disease. Am J Cardiol 2000;86:615–8.

[20] Froehlich JB, Mukherjee D, Avezum A, et al. Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes, The Global Registry of Acute Coronary Events (GRACE). Am Heart J 2006;151:1223–8.

[21] Yan BP, Zhang Y, Kong AP, et al. Borderline ankle-brachial index is associated with increased prevalence of micro- and macrovascular complications in type 2 diabetes: a cross-sectional analysis of 12,772 patients from the Joint Asia Diabetes Evaluation Program. Diab Vasc Dis Res 2015;12:334–41.

[22] Viol FX, Pastori D, Perticone F, et al. Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study. BMJ Open 2015;5:e008026.

[23] Brindle P, Beswick A, Fahey T, et al. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 2006;92:1752–9.

[24] Resnick HE, Lindsay RS, McDermott MM, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 2004;109:733–9.

[25] Clark CE, Campbell JL, Powell RJ, et al. The inter-arm blood pressure difference and peripheral vascular disease: cross-sectional study. Fam Pract 2007;24:420–6.

[26] Mehlisen J, Winberg N. Interarm difference in blood pressure: reproducibility and association with peripheral vascular disease. Int J Vasc Med 2014;2014:841542.

[27] Su HM, Lin TH, Hsu PC, et al. Association of interarm systolic blood pressure difference with atherosclerosis and left ventricular hypertrophy. PLoS One 2012;7:e41173.

[28] Canepa M, Milaneschi Y, Ameri P, et al. Relationship between inter-arm difference in systolic blood pressure and arterial stiffness in community-dwelling older adults. J Clin Hypertens (Greenwich) 2013;15:880–7.

[29] Tanaka Y, Fuku M, Tanaka M, et al. The inter-arm difference in systolic blood pressure is a novel risk marker for subclinical atherosclerosis in patients with type 2 diabetes. Hypertens Res 2014;37:548–52.
[30] Kleefstra N, Houweling ST, Logtenberg SJ, et al. Prognostic significance of between-arm blood pressure differences: between-arm blood pressure difference and mortality. Hypertension 2008;52:e14.

[31] Singh S, Sethi A, Singh M, et al. Simultaneously measured inter-arm and inter-leg systolic blood pressure differences and cardiovascular risk stratification: a systemic review and meta-analysis. J Am Soc Hypertens 2015;9:e40.e12–50.e12.

[32] Okada H, Fukui M, Tanaka M, et al. A difference in systolic blood pressure between arms is a novel predictor of the development and progression of diabetic nephropathy in patients with type 2 diabetes. Atherosclerosis 2013;230:198–201.

[33] Hirono A, Kusunose K, Kageyama N, et al. Development and validation of optimal cut-off value in inter-arm systolic blood pressure difference for prediction of cardiovascular events. J Cardiol 2018;71:24–30.

[34] Wilcox T, Newman JD, Maldonado TS, et al. Peripheral vascular disease risk in diabetic individuals without coronary heart disease. Atherosclerosis 2018;275:419–25.